No Improved Outcomes in Prostate Cancer With ADT Plus Mitoxantrone/Prednisone

Combining mitoxantrone and prednisone with adjuvant androgen deprivation therapy failed to improve overall survival over ADT alone in patients with high-risk prostate cancer.

Source: CancerNetwork - April 18, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers SiteTerms/www.cannabissciencetech.com/News Prostate Cancer Source Type: news